glutathione and fibromyalgia in Chronic Fatigue Syndrome (ME/CFS) Are Intranasal Drugs the Future

The global decline of cheetah Acinonyx jubatus and what it means for conservation

New England Journal of Medicine, 373(23), 2247-2257

Career scientists at the FDA have continued to argue that there's insufficient evidence to suggest that many substances are safe or effective

The phase 2 GeparOLA study compared paclitaxel + olaparib and paclitaxel + carboplatin in neoadjuvant settings in patients with HER2, HRD+ early breast cancer

Common and rare side effects Patients usually experience mild reactions that go away in a few hours

(Ohno S, Nakajin S, Drug MetabDispos, 37: 32-40, 2009), though mRNA and protein expression are not always well correlated, especially when comparing isoforms